Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie’s HIV drug combo shows no benefit in Covid-19 trial

Details:

The primary endpoint was the time to clinical improvement. The medication failed to improve the condition or prevent the death of severely-affected Covid-19 patients, compared to standard care.

Lead Product(s): Lopinavir,Ritonavir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 19, 2020

Abbvie Company Banner

DDF Summit 2022 US

Not Confirmed

envelop

Contact Supplier

AbbVie Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Contact Supplier

Contact Supplier

Digital Content

AbbVie Partnering with Global Authorities

Details:

The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19.

Lead Product(s): Lopinavir,Ritonavir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: European Health Authorities

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership March 09, 2020

Abbvie Company Banner

DDF Summit 2022 US

Not Confirmed

envelop

Contact Supplier

Amarin

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19

Details:

The trial objective is the effect of VASCEPA vs usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis.

Lead Product(s): Icosapent Ethyl

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

ASK
US

Upload
your Pipeline Activity

Mallinckrodt Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Mallinckrodt and Novoteris Receive Clearance from to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19

Details:

Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 got clearance from Health Canada.

Lead Product(s): Nitric Oxide

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY